CBMT-25. ANTI-TUMOR EFFECT OF VEGF INHIBITOR PLUS KETOGENIC DIET THERAPY FOR GLIOBLASTOMA

Abstract

INTRODUCTION: Malignant glioma cells depend on glucose as the main energy source. Cancer cells may not be able to metabolize ketones as efficiently as normal brain cells, the ketogenic diet (KD) has been proposed as a complementary therapy for treatment of malignant gliomas. VEGF (vascular endothelial growth factor) inhibitor (bevacizumab) decreases blood supply to tumor and clinically used for glioblastoma treatment. Therefore, we examined anti-tumor effect of the combination of bevacizumab (Bev) and KD therapy using mouse model. METHODS U87MG cells were implanted into the right brain of nude mice. One week after the implantation, mice were randomized into four treatment groups: control group, KD group, Bev group, and combination group. KetoCal 4:1 was administered to the mice for KD. Bev (10mg/kg) was injected from tail vein twice a week. Metabolic and histological analysis of the tumor, and survival analysis of the mice were performed.